June 21, 2023 - Wiesbaden, GER, and Gurgaon, IND. The International Centers for Precision Oncology (ICPO) Foundation and Fortis Memorial Research Institute (FMRI) today announced a reference center collaboration to promote international education standards in Radiomolecular Precision Oncology (RPO) and support the establishment of new Theranostics Centers in India. The partnership aims to enhance patient access to advanced RPO imaging and therapies in India and contribute to the global advancements in the field.
ICPO Foundation and FMRI have signed an agreement to advance education and infrastructure in RPO through their combined medical and scientific expertise. As part of this collaboration, ICPO and FMRI will work together to establish a state-of-the-art Theranostics Reference Center at FMRI, which will serve as a hub for RPO education, research, and clinical practice in India. The center will provide comprehensive training and education programs for medical professionals, facilitate the exchange of knowledge and best practices, and promote the adoption of standardized processes and protocols in RPO.
Through the partnership, ICPO Foundation will leverage its expertise and the ICPO Academy for Theranostics Platform to provide cutting-edge education and training resources to FMRI and its network of healthcare professionals. The ICPO Academy for Theranostics offers a wide range of e-learning modules, multi-level qualification processes, and customized online courses to equip healthcare professionals with the necessary skills and knowledge in RPO. FMRI will collaborate with ICPO to enhance the academy's content, develop country-specific translations and certifications, and contribute its expertise to further improve the platform.
Additionally, ICPO Foundation and FMRI will jointly work on expanding the ICPO Theranostics Center network to other regions in India, aiming to provide patients across the country with widespread and democratized access to RPO imaging and therapies. The establishment of a strong network of Theranostics Centers will foster innovation, facilitate multi-centric clinical research, and enable the development of targeted therapies and clinical trial designs.
“We are thrilled to enter into this strategic partnership with FMRI to advance the field of Radiomolecular Precision Oncology in India”, said Professor Vikas Prasad, Dean of ICPO Centers. “By establishing the Theranostics Reference Center at FMRI and collaborating on education and training initiatives, we aim to empower healthcare professionals, standardize clinical practices, and ultimately improve patient outcomes. Together, we can make a significant impact on the lives of patients in India and contribute to the global fight against cancer “
Dr. Ishita Sen, Senior Director and Clinical Lead, Nuclear Medicine at FMRI expressed great enthusiasm about the collaboration, stating, " We are honored to join hands with the ICPO Foundation to promote standardized education and expanded patient access to Theranostics in Precision Oncology. Thispartnership will enable us to enhance our capabilities, improve patient care, and contribute to the global efforts of advancing therapeutic nuclear medicine. We look forward to working closely with ICPO to establish the Theranostics Reference Center in India and make a positive difference in the lives of cancer patients."
Prof. Prasad added “We would like to express our gratitude to Taranjit Singh, representing BJ Madan Company, for his key role in initiating this collaboration between FMRI and ICPO and in being pivotal in advancing the mission of the ICPO in India and promoting the adoption of precision oncology practices in the country.
About ICPO Foundation
The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation is helping to build momentum to scale global patient access to Molecularly Targeted Precision Oncology to support this shift. To scale patient access, the ICPO Foundation aims to develop an international network of physical diagnostic and therapeutic Centers for Theranostics in Precision Oncology organized in a Social Franchise model based on shared know-how, certified education, and design and process standardization that enables best clinical practice globally. Furthermore, it is the ICPO Foundation’s objective to empower its Centers by embedding them in a highly inclusive Community that spearheads its model and lives up to the Precision Oncology promise, by making it available to all patients in need, irrespective of country or social status.
Learn more at: www.icpo.foundation
About Fortis Healthcare Limited
Fortis Healthcare Limited – an IHH Healthcare Berhad Company – is a leading integrated healthcare services provider in India. It is one of the largest healthcare organizations in the country with 27 healthcare facilities, 4,300 operational beds and 400 diagnostics centers (including JVs). Fortis is present in India, United Arab Emirates (UAE), Nepal & Sri Lanka. The Company is listed on the BSE Ltd and National Stock Exchange (NSE) of India. It draws strength from its partnership with global major and parent company - IHH, to build upon its culture of world-class patient care and superlative clinical excellence. Fortis employs ~23,000 people (including Agilus, earlier SRL) who share its vision of becoming the world’s most trusted healthcare network. Fortis offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services.
Learn more at: www.fortishealthcare.com
Media Contact Fortis Healthcare Limited
Dr. Ishita Sen
Phone: +91-124 4921021
Media Contact ICPO Foundation
Phone: + 49 611 341 486 30